BACKGROUND: Belotecan (Camtobell, Chong Keun Dang Corp, Seoul, Korea; CKD602) is a new camptothecin analogue. This study aimed to investigate the safety and efficacy of single-agent belotecan for small-cell lung cancer (SCLC). PATIENTS AND METHODS: Twenty-seven patients with chemotherapy-naive or chemosensitive SCLC were treated with belotecan 0.5 mg/m(2)/day on days 1-5 of a 3-week cycle. All 27 patients were assessable for toxicity, and 21 patients assessable for response. RESULTS: Nine patients (42.9%) showed objective tumor responses including one complete response; seven (63.6%) in 11 chemotherapy-naive patients; and two (20.0%) in 10 chemosensitive patients. With a median follow-up of 5 years, median progression-free and survival time for chemotherapy-naive patients were 4.8 months and 11.9 months, respectively, while the corresponding values for chemosensitive patients were 3.3 months and 10.5 months, respectively. The most common toxicity was neutropenia. CONCLUSION: Belotecan was active in SCLC patients as a single agent, warranting further investigations of belotecan in combination with platinum or other active agents.
BACKGROUND:Belotecan (Camtobell, Chong Keun Dang Corp, Seoul, Korea; CKD602) is a new camptothecin analogue. This study aimed to investigate the safety and efficacy of single-agent belotecan for small-cell lung cancer (SCLC). PATIENTS AND METHODS: Twenty-seven patients with chemotherapy-naive or chemosensitive SCLC were treated with belotecan 0.5 mg/m(2)/day on days 1-5 of a 3-week cycle. All 27 patients were assessable for toxicity, and 21 patients assessable for response. RESULTS: Nine patients (42.9%) showed objective tumor responses including one complete response; seven (63.6%) in 11 chemotherapy-naive patients; and two (20.0%) in 10 chemosensitive patients. With a median follow-up of 5 years, median progression-free and survival time for chemotherapy-naive patients were 4.8 months and 11.9 months, respectively, while the corresponding values for chemosensitive patients were 3.3 months and 10.5 months, respectively. The most common toxicity was neutropenia. CONCLUSION:Belotecan was active in SCLCpatients as a single agent, warranting further investigations of belotecan in combination with platinum or other active agents.
Authors: William C Zamboni; Suresh Ramalingam; David M Friedland; Robert P Edwards; Ronald G Stoller; Sandra Strychor; Lauren Maruca; Beth A Zamboni; Chandra P Belani; Ramesh K Ramanathan Journal: Clin Cancer Res Date: 2009-02-03 Impact factor: 12.531
Authors: Seungmin Han; Kwang Suk Lim; Brody J Blackburn; Jina Yun; Charles W Putnam; David A Bull; Young-Wook Won Journal: Pharmaceutics Date: 2022-08-16 Impact factor: 6.525
Authors: Huali Wu; Ramesh K Ramanathan; Beth A Zamboni; Sandra Strychor; Suresh Ramalingam; Robert P Edwards; David M Friedland; Ronald G Stoller; Chandra P Belani; Lauren J Maruca; Yung-Jue Bang; William C Zamboni Journal: Int J Nanomedicine Date: 2012-10-19